Viral Vector Development and Manufacturing Strategies for Scalable Programs
July 28th 2026 | 11:00am ET
Successful viral vector programs require more than manufacturing capacity. They depend on early process understanding, strong technical alignment, and scalable development strategies, platform expertise, and manufacturing approaches that support quality, regulatory expectations, and long-term supply.
Join David Sapirstein, Director of Business Development at SK pharmteco, for an overview of the company’s integrated viral vector development and manufacturing capabilities. Learn how the SKyvec™ Viral Vector Platform supports AAV, lentiviral, adenoviral, and in vivo lentiviral programs through flexible process development, manufacturing, analytical testing, fill-finish, and regulatory support from early development through commercial production.
What You’ll Learn from SK pharmteco
- Not one-size-fits-all: How platform-based approaches and custom solutions support efficient development and scalable manufacturing
- Key capabilities for AAV, lentiviral, adenoviral, and in vivo lentiviral programs
- Current manufacturing capacity and integrated services across North America and Europe
- Strategies to support process development, technology transfer, analytical testing, and regulatory readiness
- Practical considerations for advancing viral vector programs from early development to commercial manufacturing, including supporting rare disease innovators
Who Should Attend?
This webinar is intended for biotechnology and pharmaceutical professionals involved in gene therapy development, including CMC, process development, manufacturing, technical operations, business development, and regulatory teams evaluating CDMO services for viral vector development and manufacturing.
Reserve your spot today to learn how integrated viral vector development and manufacturing strategies can help advance your next gene therapy program.